US Drug Recall Register

FDA Drug Recalls

2,277 recalls · Class II, newest first

Class II · Moderate risk Ongoing

Duloxetine Delayed-Release Capsules

Reason CGMP Deviations: Presence of N-nitroso-duloxetine impurity above the recommended interim limit.

Amerisource Health Services LLC NDC 68001-415-08 D-0158-2025
Class II · Moderate risk Ongoing

Duloxetine Delayed-Release Capsules USP

Reason CGMP Deviations: Presence of N-nitroso-duloxetine impurity above the recommended interim limit.

Amerisource Health Services LLC NDC 68001-415-04 D-0157-2025
Class II · Moderate risk Ongoing

Duloxetine Delayed-Release Capsules

Reason CGMP Deviations: Presence of N-nitroso-duloxetine impurity above the recommended interim limit.

Amerisource Health Services LLC NDC 68001-414-05 D-0156-2025
Class II · Moderate risk Ongoing

Duloxetine Delayed-Release Capsules USP

Reason CGMP Deviations: Presence of N-nitroso-duloxetine impurity above the recommended interim limit.

Amerisource Health Services LLC NDC 68001-414-04 D-0155-2025
Class II · Moderate risk Ongoing

Nebivolol Tablets

Reason CGMP Deviations: Presence of Nitrosamine Drug Substance Related Impurity (NDSRI), N-Nitroso Nebivolol above acceptable intake (AI) limit.

Aurobindo Pharma USA Inc D-0149-2025
Class II · Moderate risk Ongoing

Timolol Maleate Ophthalmic Solution USP

Reason Defective Container: Unable to get the solution out of the bottle as the spike of the cap was lodged in the nozzle of the product bottle.

FDC Limited NDC 64980-513-15 D-0114-2025
Class II · Moderate risk Ongoing

Nitrofurantoin Capsules

Reason Failed Dissolution Specifications

AvKARE D-0168-2025
Class II · Moderate risk Ongoing

Duloxetine Delayed-Release Capsules

Reason CGMP Deviations; presence of N-nitroso-duloxetine impurity above recommended interim limit.

RemedyRepack Inc. NDC 70518-0937-04 D-0165-2025
Class II · Moderate risk Ongoing

Cinacalcet Tablets

Reason CGMP deviations: Presence of Nitrosamine Drug Substance Related Impurity (NDSRI), N-Nitroso-Cinacalcet above acceptable intake limit.

AvKARE NDC 42291-461-30 D-0110-2025
Class II · Moderate risk Ongoing

Cinacalcet Tablets

Reason CGMP deviations: Presence of Nitrosamine Drug Substance Related Impurity (NDSRI), N-Nitroso-Cinacalcet above acceptable intake limit.

AvKARE NDC 42291-460-30 D-0109-2025
Class II · Moderate risk Ongoing

Cinacalcet Tablets

Reason CGMP deviations: Presence of Nitrosamine Drug Substance Related Impurity (NDSRI), N-Nitroso-Cinacalcet above acceptable intake limit.

AvKARE NDC 42291-459-30 D-0108-2025
Class II · Moderate risk Ongoing

Olanzapine Tablets

Reason Failed Impurities/Degradation Specifications

Macleods Pharmaceuticals Ltd NDC 33342-067-07 D-0154-2025
Class II · Moderate risk Ongoing

VCF, Vaginal Contraceptive Gel

Reason CGMP deviations: out of specifications for assay

Apothecus Pharmaceutical Corp. NDC 52925-512-10 D-0151-2025
Class II · Moderate risk Ongoing

10 Irregular Pigmentation

Reason CGMP Deviations: Inconsistency in the water systems.

Generitech Corporation D-0111-2025
Class II · Moderate risk Ongoing

Levothyroxine Sodium Tablets

Reason Subpotent and Superpotent Drug

Mylan Institutional, Inc. D-0136-2025
Class II · Moderate risk Ongoing

Levothyroxine Sodium Tablets

Reason Subpotent and Superpotent Drug

Mylan Institutional, Inc. D-0135-2025
Class II · Moderate risk Ongoing

Levothyroxine Sodium Tablets

Reason Subpotent and Superpotent Drug

Mylan Institutional, Inc. D-0134-2025
Class II · Moderate risk Ongoing

Levothyroxine Sodium Tablets

Reason Subpotent and Superpotent Drug

Mylan Institutional, Inc. D-0133-2025
Class II · Moderate risk Ongoing

Levothyroxine Sodium Tablets

Reason Subpotent and Superpotent Drug

Mylan Institutional, Inc. D-0132-2025
Class II · Moderate risk Ongoing

Levothyroxine Sodium Tablets

Reason Subpotent and Superpotent Drug

Mylan Institutional, Inc. D-0131-2025
Class II · Moderate risk Ongoing

Duloxetine DR Capsules USP 60 mg

Reason CGMP Deviations: Presence of N-nitroso-duloxetine impurity above recommended interim limit

Rising Pharma Holding, Inc. NDC 57237-019-30 D-0107-2025
Class II · Moderate risk Ongoing

Duloxetine Delayed-Release Capsules USP

Reason CGMP Deviations: Presence of N-nitroso-duloxetine impurity above recommended interim limit

Rising Pharma Holding, Inc. NDC 57237-018-30 D-0106-2025
Class II · Moderate risk Ongoing

Duloxetine Delayed-Release Capsules USP

Reason CGMP Deviations: Presence of N-nitroso-duloxetine impurity above recommended interim limit

Rising Pharma Holding, Inc. NDC 57237-017-60 D-0105-2025